Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
BUSINESS
Takeda to Pull Lung Cancer Med Exkivity in US after Trial Miss
Takeda Pharmaceutical said on October 2 that it will voluntarily withdraw the accelerated approval granted from the US FDA for its lung cancer treatment Exkivity (mobocertinib) after the drug failed in a confirmatory trial. The Japanese juggernaut said that following…
To read the full story
Related Article
- Takeda’s Exkivity Approved in China for EGFR Exon 20+ NSCLC
January 16, 2023
- Takeda’s Exkivity Gets US Nod for EGFR Exon 20-Mutant NSCLC
September 17, 2021
BUSINESS
- Pfizer Targets Double-Digit Oncology Growth in Japan over Next 5 Years
December 16, 2025
- Obesity Market Projected at 46.6 Billion Yen by 2040 as GLP-1s Fuel Growth: Fuji Keizai
December 15, 2025
- Roche Diagnostics Taps Ex-Medtronic Japan VP Maeda as New CEO
December 15, 2025
- RaQualia Expands Alliance with HK inno.N, Licenses Japan Rights to Reflux Therapy
December 15, 2025
- Chugai to Launch US Partnering Office in January 2026
December 15, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…